Literature DB >> 23572070

Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity.

Haibin Dai1, Zhanyang Yu, Xiang Fan, Ning Liu, Min Yan, Zhong Chen, Eng H Lo, Katherine A Hajjar, Xiaoying Wang.   

Abstract

Hyperglycaemia impairs fibrinolytic activity on the surface of endothelial cells, but the underlying mechanisms are not fully understood. In this study, we tested the hypothesis that hyperglycaemia causes dysfunction of the endothelial membrane protein annexin A2, thereby leading to an overall reduction of fibrinolytic activity. Hyperglycaemia for 7 days significantly reduced cell surface fibrinolytic activity in human brain microvascular endothelial cells (HBMEC). Hyperglycaemia also decreased tissue type plasminogen activator (t-PA), plasminogen, and annexin A2 mRNA and protein expression, while increasing plasminogen activator inhibitor-1 (PAI-1). No changes in p11 mRNA or protein expression were detected. Hyperglycaemia significantly increased AGE-modified forms of total cellular and membrane annexin A2. The hyperglycemia-associated reduction in fibrinolytic activity was fully restored upon incubation with recombinant annexin A2 (rA2), but not AGE-modified annexin A2 or exogenous t-PA. Hyperglycaemia decreased t-PA, upregulated PAI-1 and induced AGE-related disruption of annexin A2 function, all of which contributed to the overall reduction in endothelial cell surface fibrinolytic activity. Further investigations to elucidate the underlying molecular mechanisms and pathophysiological implications of A2 derivatisation might ultimately lead to a better understanding of mechanisms of impaired vascular fibrinolysis, and to development of new interventional strategies for the thrombotic vascular complications in diabetes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23572070      PMCID: PMC4066328          DOI: 10.1160/TH12-12-0944

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  41 in total

1.  Potential role of recombinant annexin II in diabetic vascular injury.

Authors:  H Ishii; M Yoshida; K A Hajjar; A Tanaka; Y Yasukochi; K Shimokado; F Numano
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

2.  Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.

Authors:  H Ishii; M Yoshida; M Hiraoka; K A Hajjar; A Tanaka; Y Yasukochi; F Numano
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

3.  Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat.

Authors:  A Pandolfi; A Giaccari; C Cilli; M M Alberta; L Morviducci; E A De Filippis; A Buongiorno; G Pellegrini; F Capani; A Consoli
Journal:  Acta Diabetol       Date:  2001       Impact factor: 4.280

4.  Regulation of plasmin-dependent fibrin clot lysis by annexin II heterotetramer.

Authors:  K S Choi; S L Fitzpatrick; N R Filipenko; D K Fogg; G Kassam; A M Magliocco; D M Waisman
Journal:  J Biol Chem       Date:  2001-04-23       Impact factor: 5.157

5.  Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

Authors:  D T Eitzman; R J Westrick; Z Xu; J Tyson; D Ginsburg
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

6.  Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor.

Authors:  R Nagai; K Matsumoto; X Ling; H Suzuki; T Araki; S Horiuchi
Journal:  Diabetes       Date:  2000-10       Impact factor: 9.461

7.  Is diabetic hypercoagulability an acquired annexinopathy? Glycation of annexin II as a putative mechanism for impaired fibrinolysis in diabetic patients.

Authors:  A Gugliucci; L Ghitescu
Journal:  Med Hypotheses       Date:  2002-09       Impact factor: 1.538

8.  Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.

Authors:  V M Díaz; M Hurtado; T M Thomson; J Reventós; R Paciucci
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.

Authors:  Xiaoying Wang; Sun-Ryung Lee; Ken Arai; Seong-Ryong Lee; Kiyoshi Tsuji; G William Rebeck; Eng H Lo
Journal:  Nat Med       Date:  2003-09-07       Impact factor: 53.440

10.  Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.

Authors:  K A Hajjar; D Gavish; J L Breslow; R L Nachman
Journal:  Nature       Date:  1989-05-25       Impact factor: 49.962

View more
  8 in total

1.  Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer.

Authors:  Sai Zhang; Yangmin Hu; Yuwen Huang; Huimin Xu; Gongxiong Wu; Haibin Dai
Journal:  Oncol Lett       Date:  2015-03-26       Impact factor: 2.967

2.  Annexin A2 is a Robo4 ligand that modulates ARF6 activation-associated cerebral trans-endothelial permeability.

Authors:  Wenlu Li; Zhigang Chen; Jing Yuan; Zhanyang Yu; Chongjie Cheng; Qiuchen Zhao; Lena Huang; Katherine A Hajjar; Zhong Chen; Eng H Lo; Haibin Dai; Xiaoying Wang
Journal:  J Cereb Blood Flow Metab       Date:  2018-05-22       Impact factor: 6.200

3.  Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.

Authors:  Xiang Fan; Yinghua Jiang; Zhanyang Yu; Qi Liu; Shuzhen Guo; Xiaochuan Sun; Klaus van Leyen; MingMing Ning; Xiumei Gao; Eng H Lo; Xiaoying Wang
Journal:  Transl Stroke Res       Date:  2017-06-04       Impact factor: 6.829

4.  Electroacupuncture attenuates cervical spinal cord injury following cerebral ischemia/reperfusion in stroke-prone renovascular hypertensive rats.

Authors:  Feng Tan; Jie Chen; Yangui Liang; Minhua Gu; Yanping Li; Xuewen Wang; DI Meng
Journal:  Exp Ther Med       Date:  2014-03-12       Impact factor: 2.447

5.  Annexin A2 Deficiency Exacerbates Neuroinflammation and Long-Term Neurological Deficits after Traumatic Brain Injury in Mice.

Authors:  Ning Liu; Yinghua Jiang; Joon Yong Chung; Yadan Li; Zhanyang Yu; Jeong Woo Kim; Josephine M Lok; Michael J Whalen; Xiaoying Wang
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

Review 6.  Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.

Authors:  Yinghua Jiang; Ning Liu; Jinrui Han; Yadan Li; Pierce Spencer; Samuel J Vodovoz; Ming-Ming Ning; Gregory Bix; Prasad V G Katakam; Aaron S Dumont; Xiaoying Wang
Journal:  Transl Stroke Res       Date:  2020-11-02       Impact factor: 6.829

7.  Edaravone protected human brain microvascular endothelial cells from methylglyoxal-induced injury by inhibiting AGEs/RAGE/oxidative stress.

Authors:  Wenlu Li; Hongjiao Xu; Yangmin Hu; Ping He; Zhenzhen Ni; Huimin Xu; Zhongmiao Zhang; Haibin Dai
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

8.  Recombinant annexin A2 inhibits peripheral leukocyte activation and brain infiltration after traumatic brain injury.

Authors:  Ning Liu; Jinrui Han; Yadan Li; Yinghua Jiang; Samuel X Shi; Josephine Lok; Michael Whalen; Aaron S Dumont; Xiaoying Wang
Journal:  J Neuroinflammation       Date:  2021-08-09       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.